Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30236737 | 1.00 | RXFP1 (0.39) | RXFP1RECQLKDM4EGAAPRMT5 | |
| SCHEMBL21820246 | 0.82 | RXFP1 (0.41) | RXFP1RECQLKDM4EGAAPABPC1 | |
| SCHEMBL30237686 | 0.82 | RXFP1 (0.41) | RXFP1RECQLKDM4EGAAPABPC1 | |
| SCHEMBL21820306 | 0.81 | RXFP1 (0.38) | RXFP1RECQLKDM4EGAAPABPC1 | |
| SCHEMBL20582475 | 0.78 | CYP19A1 (0.33) | — | |
| SCHEMBL21820231 | 0.78 | MAPT (0.35) | SMN1; SMN2MAPT | |
| SCHEMBL21820278 | 0.76 | HSD17B3 (0.38) | KDM4EGAASMN1; SMN2MAPT | |
| SCHEMBL21820274 | 0.72 | NQO2 (0.51) | KDM4E | |
| SCHEMBL29411210 | 0.71 | GRM5 (0.51) | PRMT5WDR77CASP3RAB9AMAPT | |
| SCHEMBL17979154 | 0.71 | GRM5 (0.51) | PRMT5WDR77CASP3RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | Bugworks Research, Inc. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | Bugworks Research, Inc. | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | UROD, ALPI, HLA-A | RXFP1 3724/4885RECQL 363/4885KDM4E 4467/4885 |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | UROD, ALPI, HLA-A | RXFP1 3724/4885RECQL 363/4885KDM4E 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.